文献速递淋巴瘤

Mosunetuzumab联合Polatuzumab vedotin治疗BTK抑制剂后复发/难治套细胞淋巴瘤的2期研究

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
PubMed 文献 · Blood · 2026-01-01

该多中心2期研究纳入42例既往≥2线治疗(含BTK抑制剂)的复发/难治套细胞淋巴瘤患者,接受Mosun-Pola方案治疗。客观缓解率88.1%,完全缓解率78.6%,中位无进展生存18.6个月,高危亚组疗效一致,细胞因子释放综合征均为1/2级。

要点

  • Mosun-Pola在BTK抑制剂后复发/难治MCL中完全缓解率达78.6%。
  • 中位无进展生存18.6个月,高危特征亚组疗效一致。
  • 细胞因子释放综合征发生率42.9%,均为1/2级。

核心结论

  • Mosun-Pola在具有高危特征的复发/难治套细胞淋巴瘤患者中实现高完全缓解率且安全性可控。

研究设计与样本

  • 多中心2期研究,纳入42例既往≥2线治疗(包括BTK抑制剂)的套细胞淋巴瘤患者。
  • 患者接受皮下Mosunetuzumab固定疗程17周期(第1周期阶梯剂量以减轻细胞因子释放综合征)联合Polatuzumab vedotin 1.8 mg/kg静脉注射6周期。
  • 主要终点为中央评估的最佳客观缓解率。

主要发现

  • 可评估患者客观缓解率为88.1%(95%CI 74.4-96.0),完全缓解率为78.6%(95%CI 63.2-89.7)。
  • 中位随访15.9个月,中位无进展生存期为18.6个月(95%CI 13.9至不可估计)。
  • 高危亚组(Ki-67≥50%占67%,母细胞样/多形性形态占38%,TP53异常占48%)中疗效一致。
  • 细胞因子释放综合征发生率为42.9%,仅限于1/2级事件。

临床怎么用

  • 对于BTK抑制剂后复发/难治且具有高危特征的套细胞淋巴瘤患者,Mosun-Pola可作为固定疗程的门诊治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), especially those progressing after Bruton tyrosine kinase (BTK) inhibitor and/or chimeric antigen receptor (CAR) T-cell therapy and those with high-risk features, have poor outcomes. The bispecific antibody, mosunetuzumab, combined with the antibody-drug conjugate (ADC), polatuzumab vedotin (Mosun-Pola), targets CD20 and CD79b via independent cell-killing mechanisms. In this multicenter phase 2 study, patients with MCL who had received ≥2 previous lines of therapy, including a BTK inhibitor, were enrolled. Patients received outpatient fixed-duration mosunetuzumab subcutaneously (17 cycles), with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS), and polatuzumab vedotin (1.8 mg/kg IV) for 6 cycles. The primary end point was centrally assessed best objective response rate. A total of 42 patients with a median of 3 previous therapies were enrolled; 26% had previous CAR T-cell therapy. A number of patients had MCL with high-risk features (Ki-67 of ≥50%, 67%; blastoid/pleomorphic morphology, 38%; TP53 aberration, 48%). Objective response occurred in 88.1% of evaluable patients (95% confidence interval [CI], 74.4-96.0) and complete response in 78.6% (95% CI, 63.2-89.7). With a median follow-up of 15.9 months, median progression-free survival was 18.6 months (95% CI, 13.9 to not estimable). Consistent efficacy was observed in high-risk subgroups. CRS occurred in 42.9% of patients and was limited to grade 1/2 events. Mosun-Pola achieved high complete remission rates while maintaining a manageable safety profile in patients with R/R MCL exhibiting high-risk features. This is, to our knowledge, the first bispecific-ADC combination therapy study in MCL. This trial was registered at www.clinicaltrials.gov as #NCT03671018.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Budde LE, Kamdar M, Assouline SE, et al. Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study. Blood. 2026. PMID: 42013019. doi:10.1182/blood.2025032422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。